Escitalopram in Bipolar Depression: a Placebo-controlled Study of Acute and Maintenance Treatment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00464191|
Recruitment Status : Terminated (The study has been terminated because too few patients have been recruited)
First Posted : April 23, 2007
Last Update Posted : September 21, 2009
Funding: An investigator-initiated trial funded by H. Lundbeck AS.
Study design: Prospective, randomised, placebo-controlled parallel-group multicenter study.
Aim: To investigate efficacy and side effects (especially mood switches) of escitalopram,a selective serotonin reuptake inhibitor, in the acute and maintenance treatment of bipolar depression.
- Escitalopram, given in addition to mood stabilising medications, is significantly more efficacious, measured by response and remission rates than placebo in bipolar depression (the acute phase study).
- Continuation therapy with escitalopram gives significantly longer mean time to depressive relapse and fewer depressive relapses compared to placebo (the continuation study).
- The incidence of "mood switching" (defined as development of mixed episodes, mania, or hypomania according to DSM-IV criteria) do not differ significantly between escitalopram and placebo in either the acute or the continuation phases.
Patients: In- and outpatients receiving care in the specialised psychiatric services of Western Norway. The population is intended to be representative of the patients treated for bipolar depression in ordinary specialist care. Patients must have a MADRS score of at least 20 at baseline. Patients with ongoing substance abuse or dependence, organic mental illness, and non-affective psychotic symptoms are excluded.
Medication: Escitalopram 10-20 mg daily or placebo in addition to mood stabilisers. The dose of mood stabilisers must have been constant for the last six weeks prior to randomisation.
Method: Phase 1 is a eight-week acute treatment trial with six clinical assessments. Patients treated with escitalopram who have not responded after eight weeks (defined by at least 50% reduction of MADRS score compared to baseline) leave the study. Placebo non-responders are treated openly with escitalopram and repeat phase 1. Responders are re-randomised to 32 weeks of maintenance treatment (phase 2). Phase 2 has nine clinical assessments. Patients who develop hypomania, mania or depressive episodes (defined as episodes meeting DSM-IV criteria for Major Depressive Episode with MADRS scores of at least 20 points) leave the study in this phase. Patients leaving the study prematurely will be offered alternative treatment.
|Condition or disease||Intervention/treatment||Phase|
|Bipolar Disorder||Drug: escitalopram||Phase 4|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Escitalopram in Bipolar Depression: a Placebo-controlled Study of Acute and Maintenance Treatment|
|Study Start Date :||April 2006|
|Actual Primary Completion Date :||March 2009|
|Actual Study Completion Date :||March 2009|
- Phase 1:
- response rates
- remission rates
- Phase 2:
- emergence of major depressive episodes
- emergence of mania, hypomania, and mixed states.
- Phase 1:
- change on the IDS-SR
- Phase 2:
- Time spent at different depressive symptom levels as assessed by the DSM-IV diagnostic criteria.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00464191
|Nordfjord Psychiatric Centre|
|Nordfjordeid, Norway, 6770|
|Principal Investigator:||Trond F. Aarre, MD||Nordfjord Psychiatric Centre|